Author

C. Terranova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:ChIP-seq· 4 Organism:human· 4 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

K. Rai· 5 shared M. Tang· 5 shared M. Maitituoheti· 4 shared E. Orouji· 3 shared J. Schulz· 3 shared S. Sarkar· 3 shared A. Lazar· 2 shared A. Raman· 2 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

K. Rai

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

M. Maitituoheti, A. Shi, M. Tang, L.-L. Ho, C. Terranova, K. Galani, E. Keung, C. Creasy, M. Wu, J. Chen, N. Chen, A. Singh, A. Chaudhri, N. Anvar, G. Tarantino, , K. Rai

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

High Enhancer Activity is an Epigenetic Feature of HPV Negative Atypical Head and Neck Squamous Cell Carcinoma

S. C. Callahan, V. Kochat, Z. Liu, A. T. Raman, J. Schulz, C. Terranova, M. Divenko, A. Ghosh, M. Tang, C. Pickering, J. N. Myers, K. Rai

The paper identifies high enhancer activity in HPV-negative atypical HNSCC as linked to BET inhibitor resistance and upregulated signaling pathways.

bioRxiv · Sep 21, 2021Cancer Biology

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

C. Terranova, M. Maitituoheti, A. T. Raman, M. Tang, N. E. Anvar, A. K. Ghosh, S. B. Amin, J. Schulz, E. Orouji, F. Giancotti, P. Troncoso, C. J. Logothetis, T. Thompson, K. Rai

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology

Bivalent and Broad Chromatin Domains Regulate Pro-metastatic Drivers in Melanoma

C. Terranova, M. Tang, M. Maitituoheti, A. Raman, J. Schulz, S. Amin, E. Orouji, K. Tomczak, S. Sarkar, J. Oba, C. Creasy, C.-J. Wu, D. Zhao, K. Chen, L. E. Haydu, , K. Rai

The paper identifies bivalent chromatin states and broad H3K4me3 domains associated with pro-metastatic drivers in melanoma using ChIP-sequencing data from tumor samples and cell lines.

bioRxiv · Aug 1, 2019 · PreprintCancer Biology

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma

M. Maitituoheti, E. Keung, M. Tang, L. Yan, H. Alam, G. Han, A. Raman, C. Terranova, S. Sarkar, E. Orouji, S. Amin, S. Sharma, M. Williams, N. S. Samant, M. Dhamdhere, , K. Rai

This study identifies KMT2D as a tumor suppressor in melanoma, showing its loss leads to metabolic reprogramming toward glycolysis and dependence on IGF signaling, suggesting therapeutic targeting of these pathways.

bioRxiv · Dec 27, 2018Cancer Biology